David Anderson is a Partner at Ampersand Capital, Boston, MA. David joined Ampersand in 2010 and participates across many sectors in healthcare but with a special focus on CDMOs and biopharma services. David's current and past board seats include Accuratus, BioClinica, Brammer Bio, Elite One Source, Histo-Scientific Research Labs, and Key Biologics. David holds a B.Sc. from the University of Aberdeen, Scotland, a Ph.D. in Cancer Immunology from the University of Sheffield, England and an M.B.A. from Babson College, MA.